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ABSTRACT
Dashtipour K, Chen JJ, Walker HW, Lee MY: Systematic literature review of
abobotulinumtoxina in clinical trials for adult upper limb spasticity. Am J Phys Med
Rehabil 2015;94:229Y238.
Objective: The aim of this study was to elucidate clinical trial efficacy, safety,
and dosing practices of abobotulinumtoxinA (ABO) treatment in adult patients with
upper limb spasticity (ULS).
Methods: A systematic literature review was performed to identify randomized
controlled trials and other comparative clinical studies of ABO in the treatment of
adult ULS published in English between January 1991 and January 2013.
Medical literature databases (PubMed, Cochrane Library, and EMBASE) were
searched, and a total of 295 records were identified. Of these, 12 primary pub-
lications that evaluated ABO for the management of ULS were included in the final
data report.
Synthesis: Total ABO doses ranged between 500 and 1500 U for ULS.
Most of the studies in ULS showed statistically significant benefits (reduction in
muscle tone based on Ashworth score) of ABO vs. placebo. Statistical significance
was reached for most evaluations of spasticity using the Modified Ashworth Scale.
Statistically significant effects on active movement and pain were demonstrated,
albeit less consistently. ABO was generally well tolerated across the individual
studies; most adverse events reported were considered unrelated to treatment.
Adverse events considered associated with ABO treatment included fatigue,
tiredness, arm pain, skin rashes, flu-like symptoms, worsening of spasm, and
weakness.
Conclusions: On the basis of data extracted from 12 randomized clinical
studies, a strong evidence base (9/12 studies) exists for the use of ABO to reduce
ULS caused by stroke.
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The use of botulinum toxin type A (BoNT-A) as a
safe and effective focal intervention for reduction of
spasticity is supported by a robust body of evidence.
Guidelines recommend that BoNT-A should be of-
fered as a treatment option in adult upper and lower
limb spasticity as standard clinical practice1Y4 and
that the exact pattern of spasticity should be consid-
eredwhen selecting specificmuscles for injection.1 In
upper limb spasticity (ULS), BoNT injections can be
made into a variety of muscles to reduce adductor
tone in the shoulder and/or reduce flexor tone at the
elbow, the wrist, and the fingers. Injections can be
made with the aim of increasing range of motion
(passive and/or active), reducing pain, and/or achiev-
ing other functional goals (hygiene/ease of dressing).
Although there have been a number of reviews
of the efficacy of BoNT-A in themanagement of ULS,4,5
none of these have provided detailed information
about the specific products available. This is important
because the dosing schemes of each product are not
interchangeable. Education on the specifics of each
product is a key unmet need in the medical commu-
nity because the lack of direct product comparability
leads to confusion and therefore, potentially, sub-
optimal treatment. AbobotulinumtoxinA (ABO) has
been used to treat ULS in many countries outside the
United States for many years.6 The necessary clinical
trials required for registration by the Food and Drug
Administration for this common indication are now
underway.
The aims of this systematic review were
therefore to elucidate clinical trial efficacy, safety,
and dosing practices of ABO treatment in adult
patients with ULS. Such information informs the
design of new clinical trial programs and provides
an evidence-based resource for clinical practice.
METHODS
The systematic literature review presented here
is one part of a larger systematic review of all potential
indications for ABO, the results of which will be
presented separately per each relevant indication.
The literature search strategy and methods for this
systematic review were specified in advance and
documented in a protocol. Components of the pro-
tocol include the literature search strategy, screening
criteria, data extraction methods, and risk for bias
appraisal used to assess studies selected for inclusion.
Screening Criteria
Specific study characteristics of interest were de-
fined in the protocol. They include study typeV
randomized controlled trials (RCTs) and other com-
parative clinical studies; patient populationVadult
patients with ULS; treatmentVABO; and outcomesV
primary and secondary efficacy, safety, and dosing.
Literature Search Strategy and
Data Sources
The literature search strategy was developed
using a combination of Medical Subject Headings
terms and key words. Key words of relevance to the
review of ULS were AbobotulinumtoxinA (alterna-
tive spellings included Abobotulinumtoxin A and
Abobotulinum Toxin A), Dysport, spasticity, and
clinical trial. Language (English only) and date limits
(January 1991 to January 2013) were also applied.
The search was performed in three foundational and
comprehensive electronic medical literature data-
bases (PubMed, Cochrane Library, and EMBASE).
Bibliographic reference lists of systematic reviews
identified during screening were searched to identify
any relevant studies that were not identified through
the electronic database searches.
Study Selection
At level 1 screening, all publications reporting
preclinical, phase 1, prognostic/biomarker, genetic
retrospective, registry, case report, and/or noncom-
parative studies were excluded, as were letters, con-
sensus reports, editorials, and nonsystematic reviews.
Although systematic reviews and meta-analyses were
not included in their own right, they were used for
identification of additional primary studies. At level 2
screening, all publications that reported only bio-
chemical or immunologic endpoints were excluded.
Also at this stage, nonrandomized controlled phase 2
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or 3 clinical trials, comparative long-term follow-up
studies (e.g., open-label follow-up of randomized
controlled clinical trials), and comparative prospec-
tive phase 4 postmarketing trials were excluded,
provided that adequate information fromrandomized
phase 2 and phase 3 trials had been identified. Pub-
lications reporting secondary and post hoc analyses
from a previously published article were not included.
The systematic literature review process of study se-
lection was depicted in a Preferred Reporting Items for
Systematic Reviews and Meta-Analyses flow diagram.4
Data Extraction
Study methodology, patient, and treatment-
level data were extracted from the full text publi-
cations under predefined headings. Each included
study underwent quality assessment of risk for bias
based on Cochrane metrics. The quality assessment
for RCTs systematically addresses six types of bias:
selection, performance, detection, attrition, report-
ing, and other sources of bias not covered by other
domains. If non-RCTs or other study types were
deemed relevant for data extraction, quality assess-
ment was performed using Transparent Reporting of
Evaluations with Nonrandomized Designs appraisal
criteria for non-RCTs.7
Role of the Funding Source
The study was partially funded by Ipsen for
data collection and editorial support. Dr Khashayar
Dashtipour developed the protocol, and data col-
lection was coordinated and designated by RTI
Health Solutions. Aside from procuring the data
collection and editorial support, Ipsen did not
contribute to the study conduct or reporting of
results. All authors had full access to all data, con-
tributed to manuscript revisions, and had final ap-
proval for submission. Dr Khashayar Dashtipour
wrote the initial draft and had final responsibility
for the decision to submit the paper for publication.
RESULTS
Publications Identified
A total of 295 records were identified from the
medical literature databases. Of these, 12 primary
publications that evaluated ABO for the management
of ULS in adult patients were included in the final
data report.8Y19 Figure 1 shows the Preferred Re-
porting Items for Systematic Reviews and Meta-
Analyses diagram for the full systematic review of all
RCTs of ABO. Most of the studies fulfilled criteria for
low-risk reporting bias. The studies used a wide range
of outcome measures including measures of spas-
ticity (usually assessed with the Modified Ashworth
Scale [MAS]), range of movement (passive and ac-
tive), global clinical impression, activities of daily
living (ADLs), goal attainment, and caregiver burden.
Efficacy in ULS
Most of the studies (9/12) in ULS showed sta-
tistically significant benefits of ABO in decreasing
muscle tone, measured by the MAS, vs. placebo
(PBO). Statistical significance was reached for most
of the evaluations of spasticity using the MAS. Sta-
tistically significant effects on active movement and
pain were harder to achieve (studies showed posi-
tive trends). Studies that evaluated the effect on
caregiver burden showed significant benefits in favor
of treatment. Table 1 provides an overview of efficacy
and safety outcomes from each of the studies (http://
links.lww.com/PHM/A96).
Bakheit and colleagues9 (2000) investigated ef-
fective and safe dose ranges in the management of
spasticity in individuals with ULS secondary to
stroke. Eighty-two subjects were recruited and
randomized to receive injections with PBO, or three
doses of ABO: 500, 1000, or 1500 U. The subjects
received the following distribution of injections:
biceps brachii (BB), 200, 400, or 600 U (500, 1000,
and 1500 U groups, respectively), and the flexor
digitorum profundus (FDP), the flexor digitorum
superficialis (FDS), the flexor carpi ulnaris (FCU),
and the flexor carpi radialis (FCR) each received 75,
150, or 225 U (500, 1000, and 1500 U groups, re-
spectively). All injections were performed using
anatomic landmarks for guidance. The investigators
noted a reduction in spasticity as measured on the
MAS for all three doses of Dysport at week 4. In
addition, they noted an increase in range of motion
at the elbow, the wrist, and the fingers for all study
groups, but no significant difference was noted be-
tween treatment groups. Secondary outcomes in-
cluded pain measured on a visual analog scale (VAS)
as well as functional status as measured by the
Barthel Index (BI) and the Rivermead Motor As-
sessment (arm section) scale; these outcomes did
not show significant differences. It was noted in the
group receiving 1500 U of ABO that 15.8% of the
patients reported loss of the ability to voluntarily
extend their fingers. The investigators concluded
that treatment with ABO at doses of 500, 1000, and
1500 U is effective and safe; however, for those in-
dividuals with residual voluntary movement in the
affected limb, the optimal dose of ABO is 1000 U to
achieve adequate spasticity control without nega-
tively impacting voluntary movement.
Bakheit and colleagues8 (2001) further evalu-
ated the efficacy and safety of ABO in 59 individuals
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with ULS secondary to stroke. Thirty-two patients
were randomized to the PBO group and 27 patients
were randomized to the ABO group. The ABO group
received 1000 U of ABO in 2 ml of normal saline
injected into the BB (300Y400 U) and the FDS
(150Y250 U) as well as 150 U each into the FDP, the
FCU, and the FCR using anatomic landmarks for
guidance. The PBO group received injections of
PBO reconstituted in normal saline into the same
muscle groups. These investigators found that in-
jection of ABO resulted in a statistically significant
reduction in spasticity based upon the MAS score
FIGURE 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram reporting the results
of the systematic literature search.
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at week 4 when compared with PBO. Other out-
come measures, including active range of motion
at the elbow, the wrist, and the fingers; pain; BI;
as well as goal attainment, did not show signifi-
cance between group differences; however, both the
patients’ and the investigators’ global assessment
of benefit demonstrated Bsome or much improved[
for the patients receiving ABO. The authors con-
cluded that, although secondary outcomes includ-
ing pain and functional status as measured by the BI
did not show improvement, the subjects receiving
ABO likely demonstrated a clinically significant bene-
fit from the reduction in spasticity given the significant
improvement in the global assessment of benefit.
Bhakta and colleagues10 evaluated the effect of
ABO on ULS as well as the impact on disability and
caregiver burden in individuals who had experi-
enced a stroke. Twenty subjects received 1000 U
of ABO injected into upper limb muscles, and
20 subjects received PBO. The injections were per-
formed using anatomic landmarks, and the muscle
selection and doses injected into individual muscles
were at the discretion of the single injector for
the study. Spasticity was measured using the
MAS, and muscle power, joint movement, and pain
were also assessed. Level of disability (eight items)
and caregiver burden (four items) were measured
using predefined activities, such as cleaning the
palm, cutting fingernails, and dressing. All outcome
measures were collected at two baseline time points
(1 wk before injection and on the day of injection) as
well as at weeks 2, 6, and 12. The individuals who
received ABO injections demonstrated improve-
ment in disability, with less disability reported at
week 6 compared with the PBO group, and a 22%
improvement in disability score at week 6, com-
pared with a 4.7% improvement in the PBO group.
In addition, the ABO group was noted to have a
reduction in caregiver burden at week 2 and con-
tinued through week 12. Evaluation of spasticity
noted a significant improvement in finger flexor
spasticity from week 2 through week 12. Reduction
in the MAS score was noted in the elbow flexors
in the ABO group at week 2, but this was not
maintained at weeks 6 and 12. No difference was
noted between the ABO and the PBO group in re-
gard to shoulder adductor spasticity. There were no
significant differences noted between the groups in
terms of active or passive range of motion at the
shoulder or the elbow, pain, or muscle strength.
These authors concluded that the use of ABO might
be beneficial in stroke patients who have difficulty
with self-care as a result of ULS and may also reduce
caregiver burden.
Bhakta and colleagues11 later reported the ef-
fect of ABO injections on associated reactions (ARs)
in the study population above. ARs were defined as
involuntary flexion movements in the paretic arm
caused by various activities, including coughing,
sneezing, and yawning. ARs were measured in the
paretic forearm musculature using surface elec-
tromyography (EMG), whereas ARs performed on
the unaffected arm were elicited by maximum vol-
untary grip. Patient-reported outcomes of effect of
ABO on ARs were also recorded. These investigators
reported a significantly greater reduction in ARs at
week 2 in the ABO group compared with PBO. The
effect of ARs on ADLs was also evaluated. At base-
line, 33 subjects reported daily ARs, with 24 noting
that ARs interfered with ADLs. Ten of 12 subjects in
the ABO group reported a reduction in the inter-
ference of ARs with ADLs, compared with 2 of 12 in
the PBO group. These investigators concluded that
ARs can interfere with ADLs and that ABO may re-
duce these involuntary movements.
Hesse and colleagues12 investigated the effect
of ABO with or without electrical stimulation (ES)
treatment after injection on ULS in 24 subjects with
a history of stroke. Six subjects were randomized
into each treatment group: 1000 U of ABO followed
by ES treatment (30 mins, 3 days per week 3 days
after injection), 1000 U of ABO without ES, PBO
injections followed by ES, and PBO injections
without ES. Injections were performed into the
following muscles using EMG guidance: BB, 250 U;
brachialis, 250 U; FCR, 125 U; FCU, 125 U; FDP,
125 U; and FDS, 125 U. The study results indicated
that there were no significant differences in MAS
scores across the groups; however, the group re-
ceiving ABO + ES treatment demonstrated the
greatest reduction in MAS scores (P = 0.011). The
results of other measures, including limb position
at rest and ability to perform three identified ADLs,
were variable. There was a significant improvement
in the ability to clean the palm of the affected hand
as rated by the subject or the caregiver in the ABO +
ES treatment group compared with the ABO with-
out ES and PBO groups. The ABO + ES group also
trended toward better limb position at rest, specif-
ically at the wrist/fingers (P = 0.068/P = 0.059).
Contrary to other studies of ABO in ULS, this study
did not demonstrate a significant reduction in spas-
ticity, which the authors attributed to selection of
subjects with severe spasticity (mean MAS scores, 3),
as well as the fact that the subjects did not participate
in postinjection rehabilitation. The authors did sug-
gest that ES of injected muscles might enhance the
effectiveness of ABO in the treatment of ULS.
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Kong and colleagues13 investigated the effects
of ABO on shoulder pain in 17 subjects with spastic
hemiplegia caused by stroke. Eight subjects were
randomized into the treatment group and received
250 U of ABO into the pectoralis major and 250 U
into the BB using anatomic landmarks to guide the
injections, and nine subjects received PBO in-
jections into the same sites. The investigators noted
that both the ABO and PBO groups experienced a
2- to 3-point reduction in shoulder pain on the VAS,
with no statistically significant difference between
the groups. In terms of spasticity, the ABO group was
noted to have a statistically significant reduction in
tone of 1 grade on the Ashworth Scale at the shoulder
adductors and the elbow flexors at week 4. Passive
shoulder abduction was also measured at all time
points and did not demonstrate any significant dif-
ferences between the ABO and PBO groups. These
investigators concluded that, although ABO effec-
tively reduced spasticity in the shoulder adductors
and the elbow flexors, shoulder pain might not have
been improved because of low study enrollments and
other potential etiologies for shoulder pain other
than spasticity.
The efficacy of ABO on management of shoul-
der pain in spastic hemiplegia after stroke was also
investigated by Marco and colleagues.14 Fourteen
subjects were randomized to receive 400 U of ABO
into four sites in the pectoralis major muscle using
EMG guidance, and 15 subjects received PBO into
the same locations. After the injections, both groups
received 6 wks of conventional transcutaneous
electrical nerve stimulation therapy. Outcome mea-
sures were obtained at baseline, 7 days, 1 mo,
3 mos, and 6 mos. Pain scores were measured using
the 100-mm VAS, and on completion of the study,
the subjects in the ABO group demonstrated a sta-
tistically significant reduction in pain, with a mean
reduction of 46.2 mm, whereas the PBO group
noted a 21.9-mm reduction on the VAS. Secondary
outcome measures including range of motion with
shoulder flexion and abduction, spasticity according
to the MAS, as well as motor potential latency of the
pectoral nerve did not demonstrate statistically
significant differences between the groups; howev-
er, range of motion with external rotation was sig-
nificantly improved, and pectoral nerve motor
amplitudes were significantly reduced at the 1-mo
point in the ABO group. The authors concluded that
ABO is effective in treating shoulder pain and im-
proving external rotation range of motion in pa-
tients with spastic hemiplegia secondary to stroke.
McCrory and colleagues15 evaluated the effect
of ABO injections on quality-of-life in individuals
with ULS secondary to cerebrovascular accident in a
multicenter RCT. Fifty-four subjects were random-
ized into the ABO group and were given doses of
750Y1000 U of ABO at the initial treatment and then
500Y1000 U 12 wks later; 42 subjects were ran-
domized to the PBO group. The subjects received
injections of ABO or PBO into the Bprincipal spastic
muscles of the distal upper limb[; muscle selection,
number of injection sites per muscle, and use of
injection guidance with EMG or ES were at the
individual clinician’s discretion. At the 12-wk point,
the subjects received reinjection with the same
agent (ABO or PBO), with ABO doses ranging from
500 to 1000 U. The primary outcome for this study
was the quality-of-life and well-being of the subjects
as measured on the Assessment of Quality of Life
Scale; the change in Assessment of Quality of Life
Scale scores from baseline to end of study follow-up
showed no significant difference between the ABO
and PBO groups. Other patient-centered outcomes
including pain and mood also did not show a dif-
ference between the groups. Muscle spasticity as
measured on the MAS was noted to be significantly
reduced in the ABO group at all time points. The
achievement of individual goals selected from the
Patient Disability Scale reflected a functional ben-
efit in the ABO group at week 20; in addition,
modest improvements were noted in the Caregiver
Burden Scales and the Patient Disability Scale;
however, these measures did not reach statistical
significance. Global Assessment of Benefit as re-
ported by both investigators and subjects or their
guardians suggested that the ABO group had a
higher proportion of subjects with overall benefit.
Of note, in this study, the investigators reported a
wide range in the number of postinjection therapy
sessions attended by the subjects (0Y91), with a
mean of 10.8 sessions; however, 33% of the patients
did not receive any therapy. These authors con-
cluded that, although ABO injections did not result
in change in quality-of-life, ABO is safe and effective
at decreasing ULS.
Smith and colleagues16 conducted a double-
blind, PBO-controlled, dose-ranging study to
evaluate dose-response relationships in 21 subjects
with stroke (n = 19) or head injury (n = 2). The
subjects were randomized to receive injections with
PBO and 500, 1000, or 1500 U of ABO, and four of
the six PBO group subjects were rerandomized,
allowing 25 randomizations from 21 subjects. Two-
thirds of the total ABO or PBO dose was allocated to
muscles above the elbow, with the remaining one-
third distributed into the wrist flexors, the finger
flexors, and the thumb adductors/flexors. Outcomes
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measured at baseline and 2, 6, and 12 wks included
passive and active range of motion; MAS scores at
the elbow, wrist, and metacarpophalangeal joints;
patient disability as determined by the upper body
dressing time and the Frenchay Arm Test; as well as
the patient-reported Global Assessment Scale.
Using combined dose data, these investigators
reported a significant overall improvement in MAS
scores at the wrist and the fingers in the subjects
treated with ABO, as well as improved passive range
of motion increased at the wrist at week 6 follow-up,
and an increase in finger curl distance. No sig-
nificant differences were noted in the dressing time,
the Frenchay Arm Test, or postural alignment.
Fifteen subjects reported improvement in global
rating scale scores in the ABO group, compared
with only two subjects in the PBO group. Data from
individual doses revealed a significant increase in
passive range of motion at the elbow in the 1500-U
ABO group. Spasticity as measured on the MAS was
significantly reduced at the wrist in the 500-U ABO
group and trended toward a reduction in the 1500-U
ABO group (P = 0.06). These investigators con-
cluded that ABO injections increased passive range
of motion and decreased ULS in individuals with
spasticity caused by stroke or head injury, and in-
creasing the dose tended to increase the magnitude
of response at the wrist and the elbow.
Shaw and colleagues17 conducted a multicen-
ter trial evaluating the clinical effectiveness and
cost-effectiveness of ABO injections in treating ULS
in 333 individuals with spasticity secondary to
stroke. The subjects were randomized to receive
PBO injections or ABO injections into upper limb
muscles18 by trained clinicians at each site, with
total ABO dosing of 1000 U or less at each injection
visit. Both groups completed a 4-wk upper limb
therapy program after injection. Outcome assess-
ments were completed at baseline as well as at 1, 3,
and 12 mos, and clinical reassessment was com-
pleted at 3, 6, and 9 mos to determine whether the
subjects required repeated injections. The effect of
ABO injections on upper limb function as deter-
mined by the Action Research Arm Test was the
primary outcome measure for the study. Additional
measures, including upper limb impairment and
activity limitations, upper limb pain, as well as
overall quality-of-life, were also obtained using
various measures. These investigators reported that
there was no significant difference between the ABO
and PBO groups for improved arm function at 1 mo
as determined by the Action Research Arm Test
(ARAT); however, several other measures did show
significance between group differences. The ABO
group demonstrated a significant improvement in
MAS score at the elbow at 1 mo when compared
with the PBO group; however, no between-group
differences were noted at 3 and 12 mos. The ABO
group was also found to have an improvement in
upper limb strength as determined by the Motricity
Index at 3 mos; however, no differences were noted
at 1 or 12 mos. Functional measures (including dress-
ing a sleeve, cleaning the palm, and opening the hand
to cut fingernails) were significantly improved in the
ABO group (see Table 1, http://links.lww.com/PHM/A96,
for details). In terms of pain, there were no significant
between-group differences at 1 or 3 mos; however,
the ABO group had a 2-point reduction in pain on the
VAS at 12 mos compared with no change in the PBO
group. Cost analysis indicated that the addition of
ABO injections to upper limb therapy was not a cost-
effective strategy. These authors concluded that the
addition of ABO injections to a therapy program did
not result in upper extremity functional improve-
ments; however, muscle tone, limb strength, as well as
specific functional activities and pain may improve.17
Suputtitada and Suwanwela19 conducted a study
in patients with ULS caused by various neurologic
etiologies (ischemic/hemorrhagic stroke, n = 48, and
cerebral embolism, n = 2), with the goal of deter-
mining the lowest effective dose of Dysport in the
treatment of ULS. Fifty subjects were enrolled and
randomized to receive PBO or ABO in total doses of
350, 500, or 1000 U. Subjects were excluded if they
had complete plegia of the upper extremity, which
was defined as muscle strength of less than 2 of 5 in
a target segment. Injections were performed using
EMG guidance into the biceps (150, 200, or 400 U) as
well as the FCU, the FCR, the FDS, and the FDP (50,
75, or 150 U). After injections, the subjects received
therapy 3 days per week for the 6-mo study period.
Spasticity was assessed using the MAS, and pain was
assessed using the VAS at baseline as well as 2, 4, 8,
16, and 24 wks. Dexterity was evaluated using the
Action Research Arm Test, and ADLs were assessed
using the BI at baseline as well as 8 and 24 wks.
These investigators found that all three doses of ABO
significantly decreased the MAS score at week 8,
with the largest change inMAS scores in the 500- and
1000-U groups. Each of the ABO groups demon-
strated a statistically significant decrease in VAS
scores at weeks 8 and 24 when compared with PBO,
with the 500- and 1000-U groups showing a greater
reduction than the 350-U group. Statistically signif-
icant improvement in performance of ADLs as mea-
sured by the BI was noted in the 350- and 500-U
groups, with the 500-U group demonstrating the
higher change compared with the 350-U group at
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weeks 8 and 24. Dexterity as measured by the Action
Research Arm Test was statistically significantly in-
creased at weeks 8 and 24 in the 500-U group,
whereas the 1000-U group demonstrated a significant
decrease at weeks 8 and 24. These authors concluded
that 500 U is the optimal dose for treatment of ULS in
individuals with residual voluntary movement.
Yelnik and colleagues20 investigated the effi-
cacy of ABO in treating shoulder pain in subjects
with spastic hemiplegia secondary to stroke. Ten
subjects were randomized into the ABO group, with
ten patients in the PBO group. Injections of 500 U of
ABO or PBO were targeted into the subscapularis
muscle on the affected side using ES guidance,
followed by nonstandardized therapy on weekdays.
These investigators noted that pain improved as
early as 1 wk after injection, with a statistically
significant reduction in the ABO group at week 4.
Lateral (external) rotation and abduction of the arm
were assessed in both groups. External rotation was
noted to improve at weeks 2 and 4 in the ABO
group; however, no statistically significant differ-
ence was noted between groups in terms of abduc-
tion. Spasticity was measured using MAS scores at
all time points in the subscapularis muscle by pas-
sively moving the arm into lateral rotation and ab-
duction. In addition, MAS scores were recorded for
the arm muscles including the elbow flexors, the
wrist flexors, and the finger flexors. Only the finger
flexors showed a statistically significant reduction
in spasticity at the 4-wk point in the ABO group;
these researchers suggest that the finger flexor
spasticity reduction was related to the reduction in
shoulder pain and that Bspasticity in [upper limb]
muscles remote from the injection point is related
to shoulder pain.[ These researchers concluded
that injection of ABO into the subscapularis muscle
is helpful in managing shoulder pain; however,
management of ULS likely requires ABO injections
directly into all muscles affected.
Safety in ULS
ABO was generally well tolerated across the in-
dividual studies. Most adverse events reported were
considered unrelated to treatment. Adverse events
considered associated with ABO treatment included
fatigue, tiredness, arm pain, skin rashes, flu-like symp-
toms, worsening of spasm, and weakness. Treatment-
related serious adverse events were infrequent. One
study reported a case of dysphagia, which was con-
sidered potentially related to treatment.
Dosing Across Indications
Total ABO doses ranged between 500 and 1500 U
for ULS. The most commonly injected muscles were
the BB. Other injected muscles included the FDS, the
FDP, the FCU, the FCR, the flexor pollicis longus, the
pronator teres, and the pectoralis major. Dose ranges for
individual muscles are summarized overall in Table 2
(http://links.lww.com/PHM/A96) and by each individual
study in Table 3 (http://links.lww.com/PHM/A96).
DISCUSSION
Efficacy of ABO
This is the first systematic review of well
conducted trials of ABO in the management of ULS
in adult patients. Other reviews2,3 have included all
BoNT formulations (which have different dosing
schemes) and have therefore not been able to provide
detailed information on the dosing schemas used per
muscle. This is essential information because dosing
units of one BoNT-A product are not interchangeable
and cannot be converted or compared with dosing
units of another product. In this review, all studies
showed reductions in spasticity. The studies generally
showed that clinically significant (Q1 point on the
MAS)2 reductions in muscle tone were achieved
within 2 wks after injection and that the therapeutic
effect lasted approximately 3Y4 mos.
By contrast, none of the individual trials were
able to demonstrate meaningful effects of ABO on
functional improvement. Interestingly, a recent
meta-analysis of post-stroke RCTs that included
some sort of an activity outcome (e.g., Disability
Assessment Scale, Action Research Arm Test, and
BI) found that treatment with BoNT was associated
with a moderate treatment effect (standard mean
difference = 0.536 T 0.094, 95% confidence interval =
0.352Y0.721; P G 0.0001).5 This positive finding
was based on a pooled analysis of studies (7/16
studies reviewed were with ABO), and the authors
noted that there was substantial variation of effect
sizes in the individual studies because of the use of
differing outcome measures.5 Indeed, a recent re-
view of upper limb function measurement methods
found that none of the methods currently used
to assess function after BoNT treatment for ULS
satisfactorily fulfill all the criteria for a rele-
vant outcome measure when used on their own.21
Further work on developing relevant functional
outcome measures is a key unmet need in spastic-
ity research because the MAS measures muscle
tone, not spasticity. This is the fundamental prob-
lem of most of the spasticity studies. In addition,
although MAS scores are ordinal, many of the
studies used descriptive statistics as a primary
analysis to determine statistical significance. Al-
though there are limitations to this approach, the
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results do provide an indication of central tendency
(e.g., improvement from baseline or compared with
PBO), which the authors believe to be clinically
meaningful.
ABO Safety and Dosing
Current studies provide strong evidence that
ABO is a safe therapeuticmodality for ULS. As with all
botulinum toxins, an area of concern is the diffusion
of toxin into unwanted muscles. Obviously, overdos-
ing can lead to more diffusion and unwanted effects
such as weakness.22 This systematic review provides
the dose ranges of ABO that have been safely used in
the various trials. It is worth mentioning that many of
the studies used predefined doses and standardized
injection sites but that the pattern of ULS varies be-
tween patients. At least five characteristic arm post-
stroke spasticity patterns have been defined,23 and the
number of muscles and the amount of injection per
patient will frequently differ depending on the pattern
of the spasticity, size of the patient, and the residual
functionality of the affected limb.
Limitations
In this systematic review, a quality assessment
that included the risk for bias criteria presented in the
Cochrane Handbook for Systematic Reviews of In-
terventions Version 5.1.024 was applied. This resulted
in the exclusion of large uncontrolled studies and
other studies that did not meet the predefined as-
sessment criteria, which eliminated some relevant
information. It is notable that most of the trials of
ULS did not meet the criteria for inclusion in this
review because they were mostly exploratory in na-
ture. Excluding these large uncontrolled studies af-
fected this study’s sample size as well. However, a
fundamental purpose of systematic review method-
ology is to avoid bias, and this is best accomplished
by including only controlled trials.
The aim of this project was to produce a com-
prehensive, evidenced-based data report that pro-
vides information on the injection schema used and
associated outcomes for ABO. This systematic lit-
erature review focused on identifying comparative
clinical trials across countries. The heterogeneity of
outcome measures (and lack of a good functional
outcome measure) makes it difficult to directly
compare studies. Similarly, limitations result from
the heterogeneity of the timing of both the devel-
opment of post-stroke spasticity and the adminis-
tration of ABO. None of the studies posed a specific
definition in their inclusion criteria with respect to
the elapsed time between treatment and the onset
of the spasticity. Differences can be expected between
the results of injection in patients with spasticity
that occurs in the early phase after stroke, during
the first weeks, vs. late-onset spasticity at 3Y6 mos
after stroke.25 Another limitation is the fact that
most of the studies applied only a single injection
with no long-term follow-up.
Finally, it should be noted that most of the
studies on the treatment of spasticity caused by
etiologies other than stroke, such as multiple scle-
rosis, traumatic brain injury, and cerebral palsy,
were excluded because they did not meet the ran-
domized controlled study inclusion criteria.
CONCLUSIONS
On the basis of data extracted from 12 random-
ized clinical studies, a strong evidence base already
exists for the safe and effective use of ABO in post-
strokeYrelated ULS. Future clinical trial programs
required for ABO registration in the United Stateswill
be able to use the information on injection schema to
optimize trial design.
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